Indian biotechnology company Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, Reuters news agency reported on Monday, citing a source with direct knowledge of the matter.

According to the source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

The source also said that Gennova has separately submitted to India's drug regulator phase 2 trial data for its original mRNA vaccine candidate.